

PLENARY

1. **FUTURE OPPORTUNITIES FOR GLUCOSE-LOWERING THERAPIES: BARRIERS AND TARGETS**
Professor Philip Home, *UNITED KINGDOM*
2. **ENDOCRINE DISRUPTION IN OBESITY AND DIABETES: WHAT SHOULD THE CLINICIAN KNOW**
Professor Luc Van Gaal, *BELGIUM*
3. **OMICS STUDIES IN DIABETES AND DIABETIC COMPLICATIONS - WHAT HAVE WE LEARNT FROM THEM**
Professor Ronald Ching-Wan Ma, *HONG KONG*
4. **CLINICAL RELEVANCE OF NAFLD/NASH IN PATIENTS WITH TYPE 2 DIABETES**
TBA
5. **DIABETES IN THE YOUNG IN INDIA – NOVEL ASPECTS IN THE PATHOGENESIS**
Professor Nihal Thomas, *INDIA*
6. **INSULIN RESISTANCE AGAINST METABOLIC STRESS: IMPLICATIONS FOR MANAGEMENT OF T2DM-ASSOCIATED OBESITY**
Professor Christopher Nolan, *AUSTRALIA*
7. **PATIENT-CENTRIC APPROACH TO T2-DIABETES MANAGEMENT**
Emeritus Professor Morsi Arab, *EGYPT*
8. **MOBILE AND INTERNET-BASED APPS FOR DIABETES CARE**
Professor Bilal Younis, *PAKISTAN*
9. **DIABETES AND CANCERS: MINIMISING THE RISK**
Professor Ronan Roussel, *FRANCE*

MAIN SYMPOSIUM

Main Symposium 1A

1. **OPTIMISING CARE FOR PEOPLE WITH DIABETES**
 - 1.1 **Community Support Programmes for People with Diabetes**
 - 1.2 **Psychosocial Aspects of DM in Adult Population**
 - 1.3 **Enhancing Adherence to Diabetes Management: Experience of Diabetes Educator**

Main Symposium 1B

2. **CURRENT CONTROVERSIES IN DIETARY MANAGEMENT OF DIABETES**
 - 2.1 **Low GI or Low GL Foods for People with Diabetes**
 - 2.2 **Less Calorie or Less Carbo Recommended**
 - 2.3 **Nutrition Advice: Food Pyramid or Plate-Portion?**

Main Symposium 1C

3. **INSULIN IN T2DM**
 - 3.1 **Insulin Therapy for Type 2: Which, for Whom**
 - 3.2 **Insulin Analogues: Is Newer Better?**
 - 3.3 **Biosimilar Insulin - A Perspective from Asia**

Main Symposium 2A

4. **COMPLEMENTARY/ALTERNATIVE MEDICINE FOR DIABETES**
 - 4.1 **The Use of Artificial Sweeteners in DM**
 - 4.2 **Vitamins and Minerals: What Works?**
 - 4.3 **Ayurvedic Medicine for Diabetes**

Main Symposium 3A

5. DIABETES AND PREGNANCY

- 5.1 Gestational Diabetes: Controversies in Diagnosis and Management
- 5.2 Baby of A Mother with Diabetes: From Conception to Adulthood
- 5.3 Antenatal Lifestyle Intervention and Pregnancy Outcome

Main Symposium 3C

6. NOVEL APPROACHES IN MANAGING DIABETES

- 6.1 Controversies in Managing DKA
- 6.2 PCSK9-Inhibitors: A Role in Diabetes?
- 6.3 Practices and Altitude of People with Type 1 Diabetes: Implications of Management

Main Symposium 4A

7. DIABETES IN THE ELDERLY

- 7.1 Challenges in Glycaemic Control
- 7.2 Hypertension: Choice of Drugs and Targets
- 7.3 Treating Hypercholesterolaemia in the Elderly

Main Symposium 5A

8. DIABETES IN CHILDREN

- 8.1 Diabetes in Adolescents and Children - What Is the Differential Diagnosis?
- 8.2 Diabetes in Children: Challenges in Management
- 8.3 Should Dyslipidaemia in Children Be Treated?

Main Symposium 5C

9. DIABETES AND OBESITY

- 12.1 Obesity and Diabetes: An Unholy Association
- 12.2 Obesity and T2DM in Children
- 12.3 Newer Anti-Obesity Treatment

Main Symposium 6A

10. DIABETES AND CARDIOVASCULAR RISK

- 10.1 Antiglycaemic Therapy and (Risk of) Heart Failure
- 10.2 Cardiovascular Outcome Studies with New OHAs
- 10.3 Beyond Glycaemia: Strategies to (Further) Reduce CV Risks in People with T2DM

Main Symposium 6B

11. SGLT2 INHIBITION

- 11.1 Non Glycaemic Effects of SGLT2i: Clinical Implications
- 11.2 Side Effects of SGLT2 Inhibitors: What Clinicians Should Know
- 11.3 Empa-Reg Outcome: A Game Changer in Diabetes Management

EXPERTS' CASE DISCUSSION

- 1. A T2DM PATIENT WITH HT, DYSLIPIDAEMIA AND IHD
- 2. AN OBESE PERSON WITH DIABETES
- 3. A NON-COMPLIANT T2DM PATIENT

MEET THE PROFESSOR

1. **MANAGING DIABETES DURING PREGNANCY**
2. **INSULIN THERAPY**
3. **ORAL MEDICATIONS**
4. **IMPROVING PATIENTS' COMPLIANCE**
5. **CHALLENGES IN MANAGING T1DM PATIENTS**
6. **REDUCING CV COMPLICATIONS**